Customize your JAMA Network experience by selecting one or more topics from the list below.
Patients with acute venous thromboembolism (VTE) are often hospitalized for initial treatment with intravenous unfractionated heparin and coagulation monitoring by activated partial thromboplastin time (APTT). Subcutaneously administered low-molecular-weight heparin can be used in the outpatient setting and does not require APTT monitoring, which reduces costs. The Fixed-Dose Heparin trial compared the safety and efficacy of 2 treatment regimens intended for acute inpatient or outpatient treatment of VTE: fixed-dose weight-adjusted unfractionated heparin and fixed-dose weight-adjusted low-molecular-weight heparin, each combined with warfarin therapy for 3 months. In this randomized adjudicator-blinded trial reported by Kearon and colleagues,Article similar low rates of recurrent VTE and major bleeding and comparable rates (about 70%) of outpatient treatment were achieved with either treatment. In an editorial, CarsonArticle discusses the importance of assessing these treatment protocols in a double-blinded trial to ensure that safety and efficacy are not compromised by cost concerns.
This Week in JAMA . JAMA. 2006;296(8):899. doi:10.1001/jama.296.8.899
Create a personal account or sign in to: